Association of Beta-2 Microglobulin Concentrations with Frailty in Patients Undergoing Chronic Hemodialysis.

IF 2.5 Q2 UROLOGY & NEPHROLOGY

International Journal of Nephrology and Renovascular Disease Pub Date : 2025-06-10 eCollection Date: 2025-01-01 DOI:10.2147/IJNRD.S513968

Pringgodigdo Nugroho, Nur Hidayat, Kuntjoro Harimurti, Ikhwan Rinaldi, Eric Daniel Tenda, Andhika Rachman, Suryo Anggoro Kusumo Wibowo

{"title":"Association of Beta-2 Microglobulin Concentrations with Frailty in Patients Undergoing Chronic Hemodialysis.","authors":"Pringgodigdo Nugroho, Nur Hidayat, Kuntjoro Harimurti, Ikhwan Rinaldi, Eric Daniel Tenda, Andhika Rachman, Suryo Anggoro Kusumo Wibowo","doi":"10.2147/IJNRD.S513968","DOIUrl":null,"url":null,"abstract":"Introduction: Patients with Chronic Kidney Disease (CKD) undergoing regular hemodialysis experience various metabolic changes, including premature aging marked by increased prevalence of frailty. Beta-2 microglobulin (B2M), a uremic toxin whose concentration significantly increases in hemodialysis patients, has emerged as a potential biomarker of frailty. Previous evidence suggests potential link between B2M and frailty in older adults. However, data on its relationship with frailty in hemodialysis patients remains limited.Purpose: To determine the relationship between B2M concentration and frailty in hemodialysis patients.Patients and methods: This is a cross-sectional study utilizing primary data from hemodialysis patients at Rumah Sakit Cipto Mangunkusumo (RSCM), employing a total sampling method. Beta-2 microglobulin was measured using the Enzyme-Linked Fluorescent Assay (ELFA) method. Frailty was assessed using the Frailty Index 40-item. Medical history was obtained from medical records and interviews. Chi-square tests were performed to determine the relationship between B2M and frailty. Multivariate analysis was conducted to determine variables that affect frailty.Results: A total of 79 subjects participated in the study. The median B2M concentration was 32.8 (IQR 29.8-36.77). Higher B2M concentration showed a trend toward increased frailty prevalence (PR of 4.83, 95% CI 0.69-33.81, p = 0.113). The final multivariate analysis showed that sarcopenia (PR 5.37; 95% CI 2.88-10.04) was strongly and consistently associated with frailty prevalence.Conclusion: Higher B2M showed a trend towards increased frailty prevalence; however, this association is not statistically significant. Sarcopenia is a significant factor influencing the prevalence of frailty in hemodialysis patients.","PeriodicalId":14181,"journal":{"name":"International Journal of Nephrology and Renovascular Disease","volume":"18 ","pages":"151-162"},"PeriodicalIF":2.5000,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12168988/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Nephrology and Renovascular Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/IJNRD.S513968","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Patients with Chronic Kidney Disease (CKD) undergoing regular hemodialysis experience various metabolic changes, including premature aging marked by increased prevalence of frailty. Beta-2 microglobulin (B2M), a uremic toxin whose concentration significantly increases in hemodialysis patients, has emerged as a potential biomarker of frailty. Previous evidence suggests potential link between B2M and frailty in older adults. However, data on its relationship with frailty in hemodialysis patients remains limited.

Purpose: To determine the relationship between B2M concentration and frailty in hemodialysis patients.

Patients and methods: This is a cross-sectional study utilizing primary data from hemodialysis patients at Rumah Sakit Cipto Mangunkusumo (RSCM), employing a total sampling method. Beta-2 microglobulin was measured using the Enzyme-Linked Fluorescent Assay (ELFA) method. Frailty was assessed using the Frailty Index 40-item. Medical history was obtained from medical records and interviews. Chi-square tests were performed to determine the relationship between B2M and frailty. Multivariate analysis was conducted to determine variables that affect frailty.

Results: A total of 79 subjects participated in the study. The median B2M concentration was 32.8 (IQR 29.8-36.77). Higher B2M concentration showed a trend toward increased frailty prevalence (PR of 4.83, 95% CI 0.69-33.81, p = 0.113). The final multivariate analysis showed that sarcopenia (PR 5.37; 95% CI 2.88-10.04) was strongly and consistently associated with frailty prevalence.

Conclusion: Higher B2M showed a trend towards increased frailty prevalence; however, this association is not statistically significant. Sarcopenia is a significant factor influencing the prevalence of frailty in hemodialysis patients.

查看原文本刊更多论文

慢性血液透析患者β -2微球蛋白浓度与衰弱的关系

慢性肾脏疾病（CKD）患者接受定期血液透析会经历各种代谢变化，包括以虚弱患病率增加为特征的早衰。β -2微球蛋白（B2M）是一种尿毒症毒素，其浓度在血液透析患者中显著升高，已成为虚弱的潜在生物标志物。先前的证据表明B2M和老年人虚弱之间存在潜在联系。然而，其与血液透析患者虚弱关系的数据仍然有限。目的：探讨血液透析患者B2M浓度与衰弱的关系。患者和方法：这是一项横断面研究，采用全抽样方法，利用Rumah Sakit Cipto Mangunkusumo （RSCM）血液透析患者的原始数据。采用酶联荧光法（ELFA）测定β -2微球蛋白。虚弱程度采用虚弱指数40项进行评估。从病历和访谈中获得病史。采用卡方检验确定B2M与衰弱之间的关系。进行多变量分析以确定影响虚弱的变量。结果：共79名受试者参与研究。中位B2M浓度为32.8 （IQR为29.8-36.77）。B2M浓度越高，虚弱患病率越高（PR为4.83,95% CI为0.69 ~ 33.81,p = 0.113）。最终的多因素分析显示肌肉减少症(PR 5.37；95% CI 2.88-10.04)与虚弱患病率密切相关。结论：B2M越高，虚弱患病率越高；然而，这种关联在统计上并不显著。骨骼肌减少症是影响血液透析患者虚弱患病率的重要因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Nephrology and Renovascular Disease UROLOGY & NEPHROLOGY-

CiteScore

3.90

自引率

5.00%

发文量

审稿时长

16 weeks

期刊介绍： International Journal of Nephrology and Renovascular Disease is an international, peer-reviewed, open-access journal focusing on the pathophysiology of the kidney and vascular supply. Epidemiology, screening, diagnosis, and treatment interventions are covered as well as basic science, biochemical and immunological studies. In particular, emphasis will be given to: -Chronic kidney disease- Complications of renovascular disease- Imaging techniques- Renal hypertension- Renal cancer- Treatment including pharmacological and transplantation- Dialysis and treatment of complications of dialysis and renal disease- Quality of Life- Patient satisfaction and preference- Health economic evaluations. The journal welcomes submitted papers covering original research, basic science, clinical studies, reviews & evaluations, guidelines, expert opinion and commentary, case reports and extended reports. The main focus of the journal will be to publish research and clinical results in humans but preclinical, animal and in vitro studies will be published where they shed light on disease processes and potential new therapies and interventions.